Bile Acids: Their Role in Gut Health Beyond Fat Emulsification
Share this post
Supplemental bile acids and their potential for dysbiosis, constipation, and inflammatory bowel disease
Generally, when we think of bile, the role it plays in digestion is what we think of first. Produced by the liver and expelled into the digestive tract by the gallbladder (for those of us who have one), bile emulsifies and breaks down dietary fats so they can be absorbed in the small intestine. However, the effects of bile acids in the body go far beyond this.
In the digestive tract, bile acids also affect the balance of flora and gut motility;[1],[2] outside of the gut, they regulate many critical facets of physiology including glucose and cholesterol metabolism,[3] promote intracellular thyroid hormone activation,[4] and serve as signalling molecules, activating farnesoid X receptor (FXR), pregnane X receptor, the vitamin D receptor, and various G-protein coupled receptors.[5] Evidence also suggests that bile acids affect neurological function as well as the response of the hypothalamic-pituitary-adrenal axis.[6] Bile acids have even been suggested to be “novel therapeutic modalities in inflammation, obesity, and diabetes.”[7]
Although collectively referred to in the general practice of medicine as bile or the bile salt pool, the function of bile acids and their metabolites vary considerably. The human bile salt pool is primarily comprised of cholic, chenodeoxycholic, and deoxycholic acids with smaller amounts of lithocholic and ursodeoxycholic acid.[8],[9] The bile acids cholic and chenodeoxycholic acid are conjugated (by the addition of glycine or taurine) which increases their water solubility before they are released from the cells of the liver into the bile canaliculus (which feeds into the larger bile ducts and gallbladder). Certain enzymes produced by microbes in the gut deconjugate and dehydroxylate the bile acids, producing the secondary bile acids deoxycholic acid (from cholic acid) and lithocholic acid (from chenodeoxycholic acid).[10]
Bile acids have even been suggested to be “novel therapeutic modalities in inflammation, obesity, and diabetes.”
Bile salts are amphipathic in nature, having both hydrophobic and hydrophilic qualities in greater or lesser amounts depending on their conjugation and hydroxylation state.[8] Their ability to activate different receptors also varies according to their structure. Deconjugated bile acids are more hydrophobic and have greater detergent action, which increases their ability to facilitate emulsification and absorption of dietary lipids and fat soluble vitamins and to break down bacterial membranes.[11],[12] Deoxycholic acid is a particularly strong antimicrobial agent, having 10 times the antimicrobial activity of cholic acid, its precursor.[13]
Herein, we take a look at the potential of bile acids as a nutritional therapy beyond just supporting fat digestion.
Gastrointestinal impact of bile acids
The relationship between the gut microbiota and bile acids is bi-directional: bile acids affect the composition of the intestinal microbiome, and the bacteria present in the gut affect bile acid metabolism.[14] Lower levels of bile acids in the gut are associated with an overgrowth of bacteria and potential pathogens (examples being Clostridium difficile[15] and Helicobacter pylori[16]), increased inflammation, and increased bacterial translocation.[17] Bile acids have both direct and indirect antimicrobial effects: their detergent action serves to break down bacterial membranes[18] and their binding with FXR induces the secretion of antimicrobial peptides.[19] The binding of bile acids with the nuclear receptor FXR also has been shown to support intestinal barrier integrity and reduce bacterial translocation.
Small intestinal bacterial overgrowth and functional constipation
Small intestinal bacterial overgrowth (SIBO) is a common underlying issue that leads to symptoms of irritable bowel syndrome (IBS), and typically manifests with symptoms of gas, bloating, and altered bowel patterns.[20] Permanent resolution of this condition is often difficult to achieve, as many relapse when they cease following a restrictive diet or using the antimicrobials that help keep it at bay. A tool that may help resolve this condition and prevent its recurrence (particularly when it is constipation driven) that is often neglected is supplemental bile acids.
Lower levels of bile acids in the gut are associated with an overgrowth of bacteria and potential pathogens, increased inflammation, and increased bacterial translocation.
Bile acids have been shown to inhibit the growth of bacteria that produce methane (one of the gases measured in the assessment for SIBO that is associated with constipation) in vitro in a dose-dependent fashion, a finding that was supported by the results of a clinical case study as well.[21] Bile acids have been shown to reduce hydrogen production in vitro as well, likely due to their antimicrobial effects.[22] In rat models of cirrhosis and obstructive jaundice (both being conditions associated with reduced bile secretion),[23] bile acid supplementation reduced bacterial overgrowth, bacterial translocation, and the related endotoxemia,[24],[25] while in the model of cirrhosis, it also led to the normalization of bile secretion.
As a promotility agent, bile acids can help reduce the constipation that is often seen with the overgrowth of methanogenic (methane-producing) bacteria.[2],[26] Bile acids serve to hasten gut transit time by inducing fluid and electrolyte secretion as well as stimulating colonic contractions.[27] Functional constipation in approximately 15% of adults has been shown to be associated with reduced total bile acid and deoxycholic acid levels in the feces,[28] and in a smaller percentage of children also may be due to altered bile acid metabolism.[29]
As a promotility agent, bile acids can help reduce the constipation that is often seen with the overgrowth of methanogenic (methane-producing) bacteria.
Clinically, supplementation with a delayed-release preparation of chenodeoxycholate at 500 or 1000 mg/day for only four days improved bowel function and accelerated colonic transit time in women with constipation-predominate IBS, with the treatment being more effective in individuals with lower bile acid synthesis rates.[30] In healthy volunteers, supplemental chenodeoxycholate also has been shown to accelerate transit time, increasing stool frequency, ease of elimination, and completeness of evacuation.[31] Common adverse effects at both doses were lower abdominal cramping and diarrhea. It stands to reason that side effects such as these may be eliminated at lower doses, however these studies have not yet been done.
Inflammatory bowel disease
The pathogenesis of inflammatory bowel disease (IBD) also may be in part due to altered bile acid metabolism.[32] Often accompanied by dysbiosis, it shouldn’t come as a surprise that the balance of the bile acid pool is also altered in IBD. In addition to their effect on the gut microbial balance, bile acids may impact IBD through interactions with the innate and adaptive immune system, as receptors which bile acids bind (FXR and the G protein-coupled receptor, TGR5) are expressed by cells of the immune system (including macrophages, dendritic cells, and natural killer T cells) and serve to help maintain immune tolerance.[33] Bile acids also stimulate secretion of phosphatidylcholine by the cells of the liver.[34] Phosphatidylcholine is an important component of the protective intestinal mucus barrier,[35] and has been shown to be deficient (and therapeutic when applied as a treatment) in patients with ulcerative colitis.[36],[37]
In patients with IBD, lower levels of the secondary bile acids have been observed (being even lower during a flare), along with a decreased level of the gut bacteria that deconjugate bile acids.
Numerous animal models have shown that the nuclear receptor FXR and the interactions of bile acids with it affect the intestinal barrier integrity.[38] In patients with Crohn’s colitis, reduced activation of FXR in the ileum has been observed,[39] while supplementation of chenodeoxycholic acid to patients with Crohn’s was shown to increase ileal FXR activation as well as gallbladder filling.[40] An animal model of colitis supports further research in this realm, finding that treatment with an FXR-activating agent ameliorated inflammation, protected the intestinal barrier, and improved symptoms.[41]
Interactions of bile acids with TGR5 also may impacts IBD. The elimination of the genetic expression of TGR5 in animals leads to abnormal colonic mucus morphology, increased intestinal permeability, and an increased susceptibility to colitis;[42] treatment with deoxycholic and lithocholic acid or a TGR5 agonist suppresses the release of proinflammatory mediators from immune cells isolated from inflamed tissue of Crohn’s patients;[43] and numerous other animal models show that the absence or lowered expression of TGR5 leads to increased inflammation, or the stimulation of TGR5 with bile acids helps ameliorate it.[44],[45]
In patients with IBD, lower levels of the secondary bile acids (which, as mentioned, are stronger antimicrobials in addition to having a higher affinity for these bile acid receptors) have been observed (being even lower during a flare), along with a decreased level of the gut bacteria that deconjugate bile acids.[32],[46] For this reason, in addition to the potential that supplemental bile acids have for this condition, probiotics that deconjugate bile acids (in particular those that express bile salt hydrolase [BSH], known as BSH-active bacteria) have been suggested as a therapy. Notably, in a study of individuals with elevated cholesterol (a condition that BSH-active probiotics also have been shown to improve), a BSH-active probiotic (Lactobacillus reuteri NCIMB 30242) not only significantly increased levels of deconjugated bile acids in the body but also improved digestive symptoms, particularly that of diarrhea, and reduced inflammation, as assessed by high-sensitivity C-reactive protein.[47],[48]
With the broad array of functions the receptors that bile acids interact with have, and the wide distribution of these receptors throughout the body, research regarding their impact on gastrointestinal health is only but a snapshot of the important role bile acids play in maintaining homeostasis and health. Stay tuned future posts where we take a further look at bile acids and the role they play in metabolic and liver disease, as well as a diverse array of research into their application for conditions ranging from neurological disorders to allergies. And, if you can’t wait that long, learn more about the clinical experience of one physician who has found them to be a key tool for improving the condition of psoriasis!
Click here to see References
[1] Islam KB, et al. Bile acid is a host factor that regulates the composition of the cecal microbiota in rats. Gastroenterology. 2011 Nov;141(5):1773-81.
[2] Hellström PM, et al. Role of bile in regulation of gut motility. J Intern Med. 1995 Apr;237(4):395-402.
[3] Trauner M, et al. Bile acids as regulators of hepatic lipid and glucose metabolism. Dig Dis. 2010;28(1):220-4.
[4] Watanabe M, et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature. 2006 Jan 26;439(7075):484-9.
[5] Zhou H, Hylemon PB. Bile acids are nutrient signaling hormones. Steroids. 2014 Aug;86:62-8.
[6] McMillin M, DeMorrow S. Effects of bile acids on neurological function and disease. FASEB J. 2016 Nov;30(11):3658-68.
[7] Fiorucci S, Distrutti E. Bile acid-activated receptors,iIntestinal microbiota, and the treatment of metabolic disorders. Trends Mol Med. 2015 Nov;21(11):702-14.
[8] de Aguiar Vallim TQ, et al. Pleiotropic roles of bile acids in metabolism. Cell Metab. 2013 May 7;17(5):657-69.
[9] Baars A, et al. The gut microbiota as a therapeutic target in IBD and metabolic disease: a role for the bile acid receptors FXR and TGR5. Microorganisms. 2015 Oct 10;3(4):641-66.
[10] Ridlon JM, et al. Bile salt biotransformations by human intestinal bacteria. J Lipid Res. 2006 Feb;47(2):241-59.
[11] Begley M, et al. The interaction between bacteria and bile. FEMS Microbiol Rev. 2005 Sep;29(4):625-51.
[12] Islam KB, et al. Bile acid is a host factor that regulates the composition of the cecal microbiota in rats. Gastroenterology. 2011 Nov;141(5):1773-81.
[13] Kurdi P, et al. Mechanism of growth inhibition by free bile acids in lactobacilli and bifidobacteria. J Bacteriol. 2006 Mar;188(5):1979-86.
[14] Ridlon JM, et al. Bile acids and the gut microbiome. Curr Opin Gastroenterol. 2014 May;30(3):332-8.
[15] Buffie CG, et al. Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. Nature. 2015 Jan 8;517(7533):205-8.
[16] Hänninen ML. Sensitivity of Helicobacter pylori to different bile salts. Eur J Clin Microbiol Infect Dis. 1991 Jun;10(6):515-8.
[17] Slocum MM, et al. Absence of intestinal bile promotes bacterial translocation. Am Surg. 1992 May;58(5):305-10.
[18] Begley M, et al. The interaction between bacteria and bile. FEMS Microbiol Rev. 2005 Sep;29(4):625-51.
[19] Inagaki T, et al. Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc Natl Acad Sci U S A. 2006 Mar 7;103(10):3920-5.
[20] Pimentel M, et al. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol. 2000 Dec;95(12):3503-6.
[21] Florin TH, Woods HJ. Inhibition of methanogenesis by human bile. Gut. 1995 Sep;37(3):418-21.
[22] Florin TH, Jabbar IA. A possible role for bile acid in the control of methanogenesis and the accumulation of hydrogen gas in the human colon. J Gastroenterol Hepatol. 1994 Mar-Apr;9(2):112-7.
[23] Schwartz CC, et al. Bile acid metabolism in cirrhosis. V. Determination of biliary lipid secretion rates in patients with advanced cirrhosis. Gastroenterology. 1979 Dec;77(6):1177-82.
[24] Lorenzo-Zúñiga V, et al. Oral bile acids reduce bacterial overgrowth, bacterial translocation, and endotoxemia in cirrhotic rats. Hepatology. 2003 Mar;37(3):551-7.
[25] Ding JW, et al. The role of bile and bile acids in bacterial translocation in obstructive jaundice in rats. Eur Surg Res. 1993 Jan-Feb;25(1):11-9.
[26] Triantafyllou K, et al. Methanogens, methane and gastrointestinal motility. J Neurogastroenterol Motil. 2014 Jan;20(1):31-40.
[27] Kirwan WO, et al. Bile acids and colonic motility in the rabbit and the human. Gut. 1975 Nov;16(11):894-902.
[28] Vijayvargiya P, et al. Bile acid deficiency in a subgroup of patients with irritable bowel syndrome with constipation based on biomarkers in serum and fecal samples. Clin Gastroenterol Hepatol. 2018 Apr;16(4):522-7.
[29] Hofmann AF, et al. Altered bile acid metabolism in childhood functional constipation: inactivation of secretory bile acids by sulfation in a subset of patients. J Pediatr Gastroenterol Nutr. 2008 Nov;47(5):598-606.
[30] Rao AS, et al. Chenodeoxycholate in females with irritable bowel syndrome-constipation: a pharmacodynamic and pharmacogenetic analysis. Gastroenterology. 2010 Nov;139(5):1549-58.
[31] Odunsi-Shiyanbade ST, et al. Effects of chenodeoxycholate and a bile acid sequestrant, colesevelam, on intestinal transit and bowel function. Clin Gastroenterol Hepatol. 2010 Feb;8(2):159-65.
[32] Baars A, et al. The gut microbiota as a therapeutic target in IBD and metabolic disease: a role for the bile acid receptors FXR and TGR5. Microorganisms. 2015 Oct 10;3(4):641-66.
[33] Biagioli M, Carino A. Signaling from intestine to the host: how bile acids regulate intestinal and liver immunity. Handb Exp Pharmacol. 2019;256:95-108.
[34] Hofmann AF, et al. The continuing importance of bile acids in liver and intestinal disease. Arch Intern Med. 1999 Dec 13-27;159(22):2647-58.
[35] Treede I, et al. Anti-inflammatory effects of phosphatidylcholine. J Biol Chem. 2007 Sep 14;282(37):27155-64.
[36] Stremmel W, et al. Mucosal protection by phosphatidylcholine. Dig Dis. 2012;30 Suppl 3:85-91.
[37] Stremmel W, et al. Delayed release phosphatidylcholine as new therapeutic drug for ulcerative colitis–a review of three clinical trials. Expert Opin Investig Drugs. 2010 Dec;19(12):1623-30.
[38] Inagaki T, et al. Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc Natl Acad Sci U S A. 2006 Mar 7;103(10):3920-5.
[39] Nijmeijer RM, et al. Farnesoid X receptor (FXR) activation and FXR genetic variation in inflammatory bowel disease. PLoS One. 2011;6(8):e23745.
[40] van Schaik FD, et al. Pharmacological activation of the bile acid nuclear farnesoid X receptor is feasible in patients with quiescent Crohn’s colitis. PLoS One. 2012;7(11):e49706.
[41] Gadaleta RM, et al. Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. Gut. 2011 Apr;60(4):463-72.
[42] Cipriani S, et al. The bile acid receptor GPBAR-1 (TGR5) modulates integrity of intestinal barrier and immune response to experimental colitis. PLoS One. 2011;6(10):e25637.
[43] Yoneno K, et al. TGR5 signalling inhibits the production of pro-inflammatory cytokines by in vitro differentiated inflammatory and intestinal macrophages in Crohn’s disease. Immunology. 2013 May;139(1):19-29.
[44] Wang YD, et al. The G-protein-coupled bile acid receptor, Gpbar1 (TGR5), negatively regulates hepatic inflammatory response through antagonizing nuclear factor κ light-chain enhancer of activated B cells (NF-κB) in mice. Hepatology. 2011 Oct;54(4):1421-32.
[45] Perino A, et al. TGR5 reduces macrophage migration through mTOR-induced C/EBPβ differential translation. J Clin Invest. 2014 Dec;124(12):5424-36.
[46] Duboc H, et al. Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases. Gut. 2013 Apr;62(4):531-9.
[47] Jones ML, et al. Cholesterol lowering and inhibition of sterol absorption by Lactobacillus reuteri NCIMB 30242: a randomized controlled trial. Eur J Clin Nutr. 2012 Nov;66(11):1234-41.
[48] Jones ML, et al. Improvement of gastrointestinal health status in subjects consuming Lactobacillus reuteri NCIMB 30242 capsules: a post-hoc analysis of a randomized controlled trial. Expert Opin Biol Ther. 2013 Dec;13(12):1643-51.
Share this post
Dr. Carrie Decker
Related posts
The Magic of an Ancient Gum: Mastic Gum for Ulcers, Oral Health, and More
The things we know now about this gum that the Greeks have seen in practice for over 2,500 years Ancient lore and cutting-edge science often converge in the arena of natural plant-based medicine. There is perhaps no better example of this than mastic gum, an aromatic, white resin derived from the Pistacia lentiscus tree….
How the Gut Microbiome Influences COVID-19
Can probiotics reduce the risk? The COVID-19 pandemic has swept the globe, killing nearly five million people to date. The disease has a broad range of outcomes, however, with many people developing only mild to moderate symptoms like sniffles, cough, shortness of breath, and fever.[1] This extreme range of symptoms is caused by variations…
Enzymes to Help with Accidental Gluten Consumption
Many products that claim to support gluten digestion might not be fully doing the job! Celiac and other types of gluten sensitivity Celiac disease (CD) is the most studied and broadly recognized disease associated with the immune reaction to gluten consumption. Celiac disease is a multifactorial disease characterized by an inflammatory response to ingested…
The Probiotic-Cholesterol Connection
How a specific strain of Lactobacillus reuteri, NCIMB 30242, supports cardiovascular health The relationship between increasing levels of LDL-cholesterol (LDL-C) and the risk of coronary artery disease (CAD) has long been established.[1] With CAD on the rise – not to mention the chest pain and heart attacks it can lead to – the importance…
How Gut Health Keeps Kids Healthy
A blend of bifidobacteria and lactobacilli supports pediatric respiratory and skin health Achoo! Sniffle, snort! Scratch, scratch, scratch. Is allergy season here again? Or are we stuck in the dregs of cold and flu season? Wait, is there a season where kiddos aren’t dealing with some kind of infection or allergy? Could probiotics help?…
Fighting Depression and Anxiety Through the Gut
Vagus nerve stimulation for mood support (Part 2 of 2) Last week’s post examined the vagus nerve (the tenth cranial nerve) and the important role it plays in connecting the body to the brain. We explored how breath, laughter, and exercise all “tickle” the nerve to send soothing, calming signals to the brain and…
Subscribe for Updates
Categories
- Botanicals (57)
- GI Health (53)
- Healthy Aging (122)
- Immune Support (41)
- In The News (42)
- Kids Health (21)
- Stress and Relaxation (50)
- Video (9)
- Vitamins & Minerals (52)
Recent Posts
Latest Issue of FOCUS Newsletter Available Now!
About Nutrition In Focus
Subscribe for Updates
Home – About Us – Authors – Privacy Policy
Contents of this website are for the purpose of information and education only,
and not a guide to diagnosis or treatment of a particular disorder or its symptoms.
Copyright©2018-2021 Allergy Research Group®. All Rights Reserved.